Anti Viral Therapeutics News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Anti viral therapeutics. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Anti Viral Therapeutics Today - Breaking & Trending Today

ANIX Stock Price | Anixa Biosciences Inc. Stock Quote (U.S.: Nasdaq)

ANIX | Complete Anixa Biosciences Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview. ....

Anixa Biosciences Inc , Anixa Biosciences , Cancer Vaccines , Anti Viral Therapeutics , Cancer Diagnostics , San Jose , Nix Analyst Estimates , Nix Earnings Estimates , Nix Share Estimates , Nix Analyst Recommendations , Nix Ratings , Nixa Biosciences Inc Analyst Estimates , Nixa Biosciences Inc Earnings Estimates , Nixa Biosciences Inc Analyst Recommendations , Nixa Biosciences Inc Analyst Ratings ,

Anixa Biosciences' (ANIX) Buy Rating Reiterated at Chardan Capital

Chardan Capital reaffirmed their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX – Get Rating) in a research report report published on Wednesday, MarketBeat Ratings reports. They currently have a $9.00 target price on the stock, up from their previous target price of $8.00. Chardan Capital also issued estimates for Anixa Biosciences’ FY2024 earnings at […] ....

United Kingdom , Anixa Biosciences , Anixa Biosciences Company Profile , Cambridge Investment Research Advisors Inc , Us Bancorp , Anixa Biosciences Inc , Nations Financial Group Inc , Virtu Financial , International Assets Investment Management , Chardan Capital , Get Rating , Marketbeat Ratings , Anixa Bioscience , Assets Investment Management , Financial Group , Cambridge Investment Research Advisors , Cancer Vaccines , Anti Viral Therapeutics , Cancer Diagnostics , Anixa Biosciences Daily , Nasdaq Anix , Reiterated Rating ,

Anixa Biosciences' (ANIX) "Buy" Rating Reiterated at Chardan Capital

Chardan Capital reissued their buy rating on shares of Anixa Biosciences (NASDAQ:ANIX – Get Rating) in a research note published on Wednesday morning, Marketbeat.com reports. They currently have a $9.00 target price on the stock, up from their previous target price of $8.00. Chardan Capital also issued estimates for Anixa Biosciences’ FY2024 earnings at $4.61 […] ....

United Kingdom , United States , Anixa Biosciences , Geode Capital Management , America Corp , Cambridge Investment Research Advisors Inc , Ci Private Wealth , Anixa Biosciences Inc , Nations Financial Group Inc , Anixa Biosciences Company Profile , Chardan Capital , Get Rating , Anixa Bioscience , Capital Management , Investment Research Advisors , Nations Financial Group , Cancer Vaccines , Anti Viral Therapeutics , Cancer Diagnostics , Anixa Biosciences Daily , Nasdaq Anix , Reiterated Rating ,

Chardan Capital Comments on Anixa Biosciences, Inc.'s FY2024 Earnings (NASDAQ:ANIX)

Anixa Biosciences, Inc. (NASDAQ:ANIX – Get Rating) – Stock analysts at Chardan Capital issued their FY2024 EPS estimates for shares of Anixa Biosciences in a research note issued on Wednesday, March 22nd. Chardan Capital analyst M. Barcus forecasts that the company will post earnings per share of $4.61 for the year. Chardan Capital has a […] ....

United Kingdom , Anixa Biosciences , Anixa Bioscience , Cambridge Investment Research Advisors Inc , Anixa Biosciences Company Profile , Virtu Financial , Anixa Biosciences Inc , Nations Financial Group Inc , International Assets Investment Management , Us Bancorp , Get Rating , Chardan Capital , Assets Investment Management , Financial Group , Cambridge Investment Research Advisors , Cancer Vaccines , Anti Viral Therapeutics , Cancer Diagnostics , Anixa Biosciences Daily , Nasdaq Anix , Earnings Estimates ,

Anixa Biosciences (NASDAQ:ANIX) Price Target Increased to $12.00 by Analysts at HC Wainwright

Anixa Biosciences (NASDAQ:ANIX – Get Rating) had its target price lifted by HC Wainwright from $11.00 to $12.00 in a research note released on Thursday morning, The Fly reports. The firm currently has a buy rating on the stock. Separately, Chardan Capital upped their price objective on shares of Anixa Biosciences from $8.00 to $9.00 […] ....

Anixa Biosciences , Nations Financial Group Inc , Virtu Financial , Anixa Biosciences Inc , Us Bancorp , International Assets Investment Management , Get Rating , Chardan Capital , Assets Investment Management , Financial Group , Cancer Vaccines , Anti Viral Therapeutics , Cancer Diagnostics , Anixa Biosciences Daily , Nasdaq Anix , Boost Price Target , Hc Wainwright ,